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Abstract
Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and 
highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived 
recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced 
antibody and T cell responses and conferred protection against lethal challenge with a homologous 
H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to 
increase the immunogenicity of recombinant H7 hemagglutinin.
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1. Introduction
Since the first case of human infection with a novel avian H7N9 influenza virus in China in 
2013, over 650 cases with a 35% fatality rate have been reported, raising concerns about the 
pandemic potential of A(H7N9) viruses [1]. The lack of protective immunity to the virus in 
the majority of the human population highlights the critical need to develop an effective 
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vaccine to A(H7N9) virus. However, avian influenza vaccines are poorly immunogenic in 
healthy adults even at high antigen doses, unless they are adjuvanted [2]. Recently, the U.S. 
Food and Drug Administration (FDA) approved an ASO3 (oil-in-water emulsion)-
adjuvanted A(H5N1) influenza vaccine for national stockpile [3]. However, an increased 
incidence of narcolepsy in children and adults after receiving an ASO3-adjuvanted A/
H1N1pdm09 vaccine had been reported and the reasons for it were not clear [4, 5]. 
Furthermore, the precise molecular mechanisms of ASO3 in enhancing the immunogenicity 
of influenza vaccines is not known and many of the adjuvants that are approved with 
seasonal or pandemic influenza vaccines are proprietary. Effective, safe and non-proprietary 
adjuvants acting through well-defined mechanisms are therefore needed.
The innate immune system recognizes microbial structures through pattern recognition 
receptors (PRRs) [6]. Recognition of microbes by PRRs results in rapid production of 
antiviral cytokines such as type I interferons as well as pro-inflammatory cytokines for 
induction of the adaptive immune responses [7]. Retinoic-acid-inducible gene-I (RIG-I) is a 
key cytosolic receptor that recognizes 5’-triphosphate (5’ppp)-containing viral RNA in 
influenza virus infection [8] which plays a pivotal role in activating the host antiviral innate 
response. We have previously shown that in vitro activation of RIG-I with a synthetic 
5’pppRNA inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza 
virus replication [9]. In addition, we also showed that RIG-I ligand effectively enhances the 
adaptive immune response against 2009 A(H1N1) inactivated monovalent split virus vaccine 
in a mouse model [10]. In this study, we expanded our studies to explore the adjuvanticity of 
RIG-I ligand for the poorly immunogenic recombinant avian influenza hemagglutinin 
(rH7HA) protein.
2. Materials and Methods
2.1 RIG-I ligand and antigens
5' triphosphate double stranded RNA (5' ppp-dsRNA), a synthetic ligand for retinoic acid-
inducible protein (RIG-I), was purchased from Invivogen (San Diego, CA). The biological 
activity and absence of bacterial contamination of 5' ppp-dsRNA have been confirmed by the 
manufacturer. GenJet™ Plus DNA In Vivo Tranfection Reagent (SignaGen, CA) was used to 
deliver 5'ppp-dsRNA. Recombinant HA protein from A/Shanghai/2/2013 (rH7HA) influenza 
virus was expressed and purified using the baculovirus expression vector system, as 
described previously [11].
2.2 Immunization and virus challenge
Six to eight-week old female BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were 
immunized (5 animals/group) by the intramuscular (i.m.) route with 3 µg of rH7HA with or 
without 5' ppp-dsRNA or mock-immunized with PBS using 50 µl in each quadriceps muscle. 
5' ppp-dsRNA was used at concentrations of 25 µg per mouse and mixed 1:1 with GenJet™ 
Plus DNA In Vivo Transfection Reagent before immunization. Four weeks later, mice were 
boosted with the same immunization regimen. Sera were obtained three weeks post-primary 
and post-boost to determine antibody responses. Four weeks post-boost, mice were 
challenged with 50 × LD50 of wild type A(H7N9) virus (A/Anhui/1/2013, AH1) and 
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monitored for weight loss and survival for 15 days. Animal research was conducted under 
the guidance of the CDC’s Institutional Animal Care and Use Committee in an Association 
for Assessment and Accreditation of Laboratory Animal Care International-accredited 
animal facility. Mice that lost >25% of their pre-infection body weight were euthanized.
2.3 Cell-mediated immune responses
Single cell suspensions were prepared from spleen and bone marrow one week after the 
boost immunization. To detect intracellular cytokine production, 1 × 106 cells from spleen 
were stimulated in vitro with a reassortant virus containing HA and NA from A/Shanghai/
2/2013(H7N9) and the remaining six gene segments from A/Puerto Rico/8/1934-(PR8) 
[IDCDC-RG32A] here after referred to as SH2/PR8, at an MOI of 1 for 16 h with 
GolgiPlug™ (BD Bioscience, San Jose, CA) added during the last 6 h of incubation. Cells 
were surface stained with either anti-CD4 or anti-CD8 antibody (BD Bioscience), followed 
by intracellular staining with anti-IFN-γ antibody (BD Bioscience). Samples were analyzed 
using an LSRII Flow cytometer (BD Biosciences), and the cytometric data were analyzed 
using FlowJo software version 9.3.3 (Tree Star, Inc., Ashland, OR).
The frequency of HA-specific antibody-secreting cells (ASCs) in the spleen and bone 
marrow was detected by an ELISPOT assay. Briefly, 1–1.5 × 106 cells were added onto 
antigen-coated plates and incubated overnight at 37°C in a humidified atmosphere with 5% 
CO2. The plates were incubated with biotinylated anti-mouse IgG (Southern Biotech, 
Birmingham, AL) followed by alkaline phosphatase-conjugated streptavidin and developed 
with Vector Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories, Burlingame, 
CA). Spot forming units were counted using ImmunoSpot® (Cellular Technology Ltd., 
Shaker Heights, OH) and expressed as a percentage of antigen-specific IgG secreting B cells 
out of the total IgG-secreting B cells.
2.4 Serological responses
Sera from all mice were subjected to treatment overnight with receptor-destroying enzyme 
(RDE) from Vibrio Cholerae (Denka Seiken, Tokyo, Japan) at 37°C to destroy non-specific 
serum inhibitor activity. Hemagglutination inhibition (HI) antibody titers were determined 
using 4 hemagglutination units of SH2/PR8 viruses and horse red blood cells.
2.5 Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad 
Software, La Jolla, CA). Groups were compared by one-way ANOVA followed by Tukey’s 
multiple comparison test. The Mann–Whitney U test was used to determine significance of 
antibody (HI) titers. The Log-Rank (Mantel-Cox) test was used to compare percent survival 
among groups of mice. Data were presented as mean ± SEM. All differences were 
considered statistically significant when the p value was ≤0.05.
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3.1 RIG-I ligand enhanced antibody responses
Protection against influenza virus infection is primarily mediated by neutralizing antibodies. 
Recombinant influenza H7 hemagglutinins from A/Netherlands/219/2003 (H7N7) and 
A/New York/107/2003 (H7N2) have been shown to be poorly immunogenic and induce 
lower neutralizing antibody titers in mice than do seasonal hemagglutinins [12]. Therefore, 
we examined whether RIG-I ligand can enhance antibody responses against poorly 
immunogenic H7 protein. Mice were immunized using a prime-boost regimen at week 1 and 
4 as described in the Materials and Methods. Sera were collected three weeks after primary 
and booster immunization to measure HI titers against A(H7N9) virus (SH2/PR8). No 
detectable HI titers were observed in any vaccine group following primary immunization 
(Fig. 1a). Upon booster immunization, mice immunized with unadjuvanted rH7HA still did 
not display detectable HI titers. In contrast, mice immunized with rH7HA with RIG-I ligand 
developed significantly higher HI titers (p<0.05) (Fig. 1a) indicating that RIG-I ligand 
enhanced antibody responses induced by rH7HA protein.
3.2 RIG-I ligand increased the functional T cell immune responses
Cell-mediated immune responses are critical for antibody production by B cells in response 
to influenza virus infection or vaccination [13]. To evaluate the cell-mediated immune 
responses, 6 to 8-week old BALB/c mice were immunized (i.m.) with 3 µg of rH7HA with 
or without RIG-I ligand (5’pppRNA) or mock-immunized with PBS. Four weeks later, mice 
were boosted with the same formulation. Spleens were harvested one week post-boost and 
cells were re-stimulated in vitro with SH2/PR8 virus. Functional CD4 and CD8 T cells were 
analyzed by surface CD44 expression and intracellular cytokine production. The percentage 
of activated CD44+CD4 or CD44+CD8 T cells was similar among all groups (Fig. 1b). 
However, in response to in vitro A(H7N9) virus re-stimulation, the percentage of IFN-γ 
producing CD44+CD4 or CD44+CD8 T cells was significantly increased in mice that 
received rH7HA with 5’pppRNA (p<0.01 for CD4 T cells and p<0.05 for CD8 T cells) (Fig. 
1c), compared to mice immunized with rH7HA alone or PBS. Therefore, addition of RIG-I 
ligand significantly increased the frequency of antigen-responsive functional CD4 and CD8 
T cells in the spleen.
3.3 RIG-I ligand enhanced the memory B cell responses
The H7HA antigen-specific B cell responses in the spleen and bone marrow at one week 
post boost immunization were examined by ELISPOT assay. As shown in Fig. 1c, mice 
immunized with rH7HA without RIG-I ligand displayed either very low or undetectable 
H7HA-specific IgG secreting cells in the spleen and bone marrow. In contrast, the number of 
H7HA protein-specific IgG ASCs in both spleen and bone marrow was significantly 
increased in the presence of RIG-I ligand, suggesting that the addition of RIG-I ligand 
significantly enhanced memory B cell responses in both primary and secondary lymphoid 
tissues (p<0.01 in spleen and p<0.001 in bone marrow) (Fig. 1d).
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3.4 Addition of RIG-I ligand to rH7HA protein enhanced the protective immunity against 
viral challenge
To assess protective immunity, mice were challenged with a 50 LD50 of wild-type A(H7N9) 
virus (A/Anhui/1/2013, AH1). All mice immunized with rH7HA alone or PBS lost body 
weight dramatically and succumbed to infection by day 7 post-challenge. However, mice 
immunized with rH7HA adjuvanted with 5’pppRNA had minimal body weight loss (p<0.05 
for day 3 post challenge and p<0.001 for day 4–8 post challenge) (Fig. 2a) and survived 
A(H7N9) virus challenge (p<0.05) (Fig.2b). Therefore, addition of RIG-I ligand 
significantly enhances the protective immunity conferred by rH7HA protein.
4. Discussion
To meet the global demand in the event of a pandemic with avian influenza viruses, a 
number of strategies (egg-dependent and egg-independent) to manufacture influenza 
vaccines as well as adjuvants to improve their immunogenicity and provide a dose-sparing 
effect are being explored [14, 15]. Cell-based vaccines, virus-like particle (VLP), viral-
vector delivery and recombinant viral protein production technologies overcome the vaccine 
production bottleneck especially when the supply of embryonated hen eggs, the substrate for 
conventional vaccine production, is impacted due to avian influenza. The recent outbreak of 
A(H7N9), a low pathogenic avian influenza A virus with first reported human fatal 
outcomes, underscores the need for a highly immunogenic vaccine to prevent A(H7N9) 
virus infection. In this study we investigated the utility of rH7HA protein as a potential 
candidate vaccine. Avian influenza vaccines, including H7 vaccines, whether egg- or cell-
derived, recombinant proteins or live attenuated influenza viruses (LAIV), have been shown 
to be poorly immunogenic and required adjuvants to enhance their immunogenicity [12, 16–
18].
The innate immune system recognizes influenza virus through members of at least three 
distinct classes of PRRs, including Toll-like receptors, RIG-I and the NOD-like receptor 
family member, which are essential and sufficient for the induction of innate immune 
defense and type I interferon response [19]. Hence, RIG-I ligands have potential utility as 
vaccine adjuvants. In a previous study, we demonstrated that RIG-I ligand, a 5’ppp-dsRNA, 
not only enhanced the immunogenicity of a pandemic H1N1 monovalent vaccine but also 
achieved dose-sparing effect and conferred protective immunity by activating the RIG-I 
pathway [10]. This was accomplished by enhancing the frequency of follicular CD4 T helper 
cells and germinal center B cells. Furthermore, RIG-I activation was shown to be superior to 
both TLR ligands and alum adjuvant for induction of A(H1N1) influenza virus-specific 
antibody responses [10]. In our current study, we further extended our earlier observations 
on the utility of RIG-I ligand by showing that it acts as a potent molecular adjuvant even for 
poorly immunogenic H7 avian influenza vaccine. Our results demonstrated that the RIG-I 
ligand (5’pppRNA)-adjuvanted rH7HA protein is highly immunogenic and confer complete 
protection against homologous A(H7N9) viral challenge. Consistent with our previous 
report with H1N1 monovalent vaccine, we extended earlier findings and demonstrated that 
5’ppp-dsRNA also increased functional CD4 T cell and B cell responses to rH7HA[10]. In 
addition, functional CD8 T cell responses was significantly increased in mice that received 
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rH7HA with 5’pppRNA. CD8 T cell responses against influenza viruses are the major 
mediators to provide heterosubtypic immunity [20]. Thus, utility of RIG-I ligand as adjuvant 
will be an advantage in broadening protective immunity to viruses with new pandemic 
potential.
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Figure 1. RIG-I activation enhanced serum antibody responses and cell-mediated immune 
responses
BALB/c mice (5 animals/group) were immunized intramuscularly (i.m.) with recombinant 
H7HA protein (3 µg) with or without 5’pppRNA or mock-immunized with PBS as control. 
Mice were boosted one month later with the same immunogen formulation as they received 
previously. (a) Serum samples were collected three weeks post- primary and three post- 
booster immunizations and HI titers were measured against SH2/PR8 virus (*p<0.05 as 
compared to H7HA and PBS group). (b–c) Spleens were collected at 1 week after booster 
immunization and single cell suspensions were prepared. Cells were stimulated in vitro with 
SH2/PR8 virus (MOI=1) overnight with GolgiPlug™ added in the last 6 hours of incubation. 
The percentage of CD44+ activated CD4+ or CD8+ T cells were measured by surface 
staining of CD44 (b); the percentage of IFNγ-producing activated CD4+ or CD8+ T cells 
were then measured by intracellular cytokine staining (c, **p<0.01 or *p<0.05 as compared 
to H7HA and PBS group). (d) Spleen and bone marrow samples were collected at one week 
post-boost and the frequency of recombinant H7HA protein-specific IgG+ ASCs was 
measured using the ELISPOT assay. The percentage of HA-specific IgG+ ASCs in total 
IgG+ ASCs are presented (**p<0.01 or ***p<0.001 as compared to H7HA and PBS group). 
The error bars represent standard error of the means (SEM).
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Figure 2. Addition of RIG-ligand to rH7HA protein enhanced the protective immunity against 
viral challenge
BALB/c mice (5 mice/group) were immunized intramuscularly (i.m.) with recombinant 
H7HA protein (3 µg) with or without 5’pppRNA or PBS control. Mice were boosted one 
month later with the same vaccine formulation they received earlier. Immunized mice were 
challenged with 50 LD50 of wild type A(H7N9) virus and weight loss (*p<0.05 or 
***p<0.001 as compared to H7HA and PBS group) (a) and survival (*p<0.05 as compared 
to H7HA and PBS group) (b) were monitored for 15 days post-challenge. The error bars 
represent standard error of the means (SEM).
Cao et al. Page 9
Cell Immunol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
